ORIGINAL ARTICLE

Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review

Tao Zhang†, Kunpeng Xu†, Nan Bi, Li Zhang, Wei Jiang, Jun Liang, Lei Deng, Xin Wang, Jianyang Wang, Jie Wang & Luhua Wang

1 Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Department of Radiation Oncology, National Cancer Center/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
4 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Keywords
Chinese; PD-1; PD-L1; pneumonitis.

Correspondence
Nan Bi, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China.
Tel: +86 135 2044 5135
Fax: +86 10 6770 6153
Email: binan_email@163.com

Luhua Wang, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Hospital, Chinese Academy of Medical Sciences and Shenzhen Hospital, 113 Baohe Road, Longgang District, Shenzhen, Guangdong Province 518116, China.
Tel: +86 136 0128 3715
Fax: +86 10 6770 6153
Email: wfhwq@yahoo.com

†These authors contributed equally to this paper.

Received: 20 June 2020;
Accepted: 3 August 2020.

do: 10.1111/1759-7714.13631

Thoracic Cancer 11 (2020) 2916–2923 © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The PACIFIC study has defined a new standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) in the form of immune checkpoint inhibitor (ICI) consolidation therapy. However, there is little specific data pertaining to the safety and efficacy of this approach in Chinese NSCLC patients.

Methods: This was a prospective multicenter cohort study. Between September 2018 and January 2020, patients with unresectable stage III NSCLC that had undergone chemoradiation therapy (CRT) and ICI consolidation treatment were enrolled in this study. The short-term safety, tolerability, and efficacy of ICI combination with CRT were evaluated in these patients.

Results: Of the 20 Chinese patients eligible for inclusion, 17 (85.0%) underwent concurrent CRT treatment. In these patients, a median period of 40.5 days (range: 1–85 days) passed between the end of CRT and initiation of consolidation therapy. Pneumonitis occurred in 80.0% of patients, with seven (35.0%) being diagnosed with grade 1 pneumonitis and nine (45.0%) with grade 2 pneumonitis. No patients experienced grade 3 or higher pneumonitis or other ICI-related toxicities. The overall response rate (ORR) in these patients was 95.0%. Over a median follow-up period of 11.3 months (range: 6.2–21.8 months), 12-month PFS of these patients were 89.5% (95% CI: 76.7–100.0%), and 12 months OS was 100.0%.

Conclusions: These data indicate that ICI consolidation therapy can achieve favorable short-term efficacy, while exhibiting good safety and acceptable toxicity profiles in Chinese patients with unresectable stage III NSCLC.

Key points

Significant findings of the study: This is the first report evaluating the safety and efficacy of ICI consolidation therapy after chemoradiotherapy in China. Our results indicate that ICI consolidation is associated with favorable efficacy and no severe pneumonitis incidence in Chinese patients undergoing both anti-PD-1 and anti-PD-L1 monoclonal antibody consolidation.
What this study adds: Post-hoc analysis of the Japanese subgroup in the PACIFIC study suggested that consolidation therapy may be associated with increased pneumonitis incidence in Asian patients. However, our findings indicate that consolidation therapy is safe and tolerable in Chinese patients with unresectable stage III NSCLC.

Introduction

Lung cancer is among the most prominent causes of cancer-associated death in men and women. Between 80% and 85% of lung cancer cases are of the non-small cell lung cancer (NSCLC) subtype, and upwards of 30% of NSCLC patients have locally advanced disease upon initial diagnosis. Historically, the five-year overall survival (OS) rate for locally advanced NSCLC patients undergoing definitive concurrent chemoradiotherapy (cCRT) treatment has been reported to be 20%–30%. Despite countless efforts to improve the prognosis of these patients over recent decades, little progress had been made prior to the advent of immune checkpoint inhibitor (ICI) therapy.

Chemoradiotherapy (CRT) treatment has been shown to drive immunogenic cell death (ICD) in preclinical settings, and this, in turn, has been linked to clinical benefit in the context of combination immunotherapy. In the PACIFIC phase III randomized clinical trial, consolidative programmed death ligand-1 (PD-L1) inhibition using durvalumab following cCRT was associated with significant improvements in both the progression-free survival (PFS) and OS of these NSCLC patients relative to cCRT alone. The phase II single-arm LUN 14–179 study and the phase II DETERRED trial similarly assessed the safety and efficacy of consolidation therapy using pembrolizumab (anti-PD-1) or atezolizumab (anti-PD-L1) in patients with stage III unresectable NSCLC that did not exhibit disease progression following cCRT. The results of the PACIFIC study have led to the establishment of consolidative ICI therapy as a new standard of care in those with stage III NSCLC.

While ICI consolidation following cCRT is associated with significant survival benefits, it is also linked to relatively high rates of toxicity and adverse events. For example, overall radiation pneumonitis occurred in 33.9% of patients in the PACIFIC study and 24.8% of patients in placebo group in the PACIFIC study, respectively, with grade 3 and grade 4 disease occurring in 3.4% and 2.6% of these patients, respectively. Similarly, in the LUN 14–179 study, 17.2% of patients developed grade ≥2 pneumonitis, while five (5.4%) developed grade 3–4 pneumonitis, and there was one pneumonitis-related death. Pneumonitis also occurred more frequently in Asian patients than in non-Asian patients in these studies (54.2% vs. 14.1% for any pneumonitis and 5.6% vs. 1.0% for ≥grade 3 pneumonitis, respectively), potentially reflecting ethnicity-related differences in immune functionality. Notably, no Chinese cohorts were included in the PACIFIC study, and at present, there is little data available regarding the safety and efficacy of ICI consolidation following CRT in Chinese stage III NSCLC patients. As such, we designed this prospective study in order to evaluate the feasibility, tolerability and efficacy of ICI consolidation after CRT in patients with unresectable stage III NSCLC in China.

Methods

Patient eligibility

Safety and efficacy data were prospectively collected for patients with American Joint Committee on Cancer (AJCC) eighth edition stage III NSCLC that had undergone CRT with curative intent at three institutions between September 2018 and January 2020 followed by ICI consolidation therapy without disease progression.

Only patients with histologically/cytologically confirmed unresectable stage III NSCLC and an Eastern Cooperative Oncology Group performance status of 0–2 were eligible for inclusion in the present study. Gene mutation testing was performed for patients with adenocarcinoma carcinoma. This trial protocol was approved by the ethics review boards of Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.

Study design and treatment

Patients in this study underwent cCRT or sequential CRT and chemotherapy using platinum-based regimens recommended by the NCCN guidelines, including etoposide/cisplatin, paclitaxel/carboplatin, and pemetrexed/cisplatin.

All patients underwent intensity-modulated radiation therapy (IMRT) or volumetric intensity-modulated arc therapy (VMAT). The gross tumor volume (GTV) was defined as the volume of metastatic lymph nodes in hilar and mediastinum if metastatic lymph nodes were present. The clinical target volume (CTV) included the primary tumor volume plus a 0.6–0.8 cm margin, as well as involved ipsilateral hilum and mediastinal nodal stations. In patients treated via simultaneous integrated boost (SIB) radiotherapy, planning GTV...
(PGTV) was defined as the sum of GTV and GTVnd with a 5 mm expansion. The prescribed SIB-IMRT dose was 95% PGTV 60.2 Gy/2.15 Gy/28F, 95% PTV 50.4 Gy/1.8 Gy/28F, and the conventional IMRT dose was 95% PTV 50.0–60 Gy/2–2.2 Gy/23–30F. The mean dose to the lungs (MLD) was not to exceed 18 Gy, and the volume of normal lung receiving >20 Gy (V20) and 30 Gy (V30) was limited to <28% and <20%, respectively.

Patients that underwent ICI consolidation treatment were those without disease progression or radiation pneumonitis (RP) following CRT.

Evaluation and follow-up

Baseline patient evaluations consisted of chest and abdominal computed tomography (CT) scans, brain CT or magnetic resonance imaging (MRI) scans, bronchoscopy and radionuclide bone scanning. Positron emission tomography (PET)-CT scans were also recommended but not mandatory.

Follow-up evaluation in these patients consisted of patient history, physical examination, chest and abdominal CT conducted every two months during the first year and every 12 weeks thereafter. Additional imaging was performed if recurrence was suspected.

The Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria were used to assess tumor therapeutic responses.15 Treatment-related toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC), version 5.0. PFS was defined as the period between diagnosis initiation and death, tumor progression, or most recent follow-up. OS was defined as the period between diagnosis initiation and death, or most recent follow-up.

Statistical analysis

Kaplan-Meier methods were used to assess patient survival. Categorical variables are given as numbers and percentages, while continuous variables are given as means ± standard deviations. Data were compared via chi-squared tests and Student’s t-tests, as appropriate. All P-values were two-sided, with P < 0.05 as the significance threshold. STATA v16.0 (StataCorp, TX, USA) was used for all statistical testing in this study.

Results

Cohort characteristics

In total, 20 NSCLC patients were enrolled in this study between September 2018 and January 2020. These patients had a median age at diagnosis of 61 years (range: 43–78). Of these patients, 16 (80.0%) were male, and 14 (70.0%) had a history of smoking. One patient (5.0%) had stage IIB disease, seven patients (35.0%) had stage IIIA disease, eight patients (40.0%) had stage IIIB disease, and four patients (20.0%) had stage IIIC disease. The most common primary diagnoses in these patients were squamous cell carcinoma (45.0%) and adenocarcinoma (50.0%). No EGFR or ALK mutation were detected in patients with adenocarcinoma. The characteristics of patients are shown Table 1.

| Table 1 Baseline participant characteristics in the overall patient cohort |
|-----------------------------------------------|------------------|
| N (%)                                         | Overall (n = 20) |
| Age (median,range)                            | 61 (43–78)       |
| Gender                                       |                  |
| Female                                       | 4 (20.0)         |
| Male                                         | 16 (80.0)        |
| Smoking                                      |                  |
| Yes                                          | 14 (70.0)        |
| No                                           | 6 (30.0)         |
| Histology                                    |                  |
| ACC                                          | 9 (45.0)         |
| SCC                                          | 10 (50.0)        |
| NSCLC                                        | 1 (5.0)          |
| Stage                                        |                  |
| IIB                                          | 1 (5.0)          |
| IIIA                                         | 7 (35.0)         |
| IIIB                                         | 8 (40.0)         |
| IIIC                                         | 5 (20.0)         |
| SIB                                          |                  |
| Yes                                          | 15 (75.0)        |
| No                                           | 6 (25.0)         |
| cCRT                                         |                  |
| Yes                                          | 17 (85.0)        |
| No                                           | 3 (15.0)         |
| Dose (Gy, median, range)                      | 60.2 (50.0–65.0) |
| MLD (Gy, median, range)                      | 11.40 (1.49–15.00) |
| Lung V20%                                    | 19.7 (1.76–27.0) |
| Lung V30%                                    | 14.8 (1.37–20.3) |

ACC, adenocarcinoma; cCRT, concurrent chemoradiotherapy; Gy, Gray; MLD, mean dose to the lungs; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma.

Treatment

Of the patients enrolled in this study, 17 (85.0%) received cCRT and three (15.0%) received sequential CRT. The cCRT regimen included cisplatin and etoposide (n = 10, 50.0%), pemetrexed and cisplatin (n = 6, 30.0%), or paclitaxel and nedaplatin (n = 1, 5.0%). The median radiation dose was 60.2 Gy (range: 50 Gy–60.2 Gy). In total, 15 patients received SIB-IMRT and five received conventional IMRT. The median MLD was 11.40 Gy (range: 1.49 Gy–15.00 Gy), the median lung V20 was 19.7% (range: 1.76%–27.0%) and V30 was 14.8% (range: 1.37%–20.3%).

The median time between radiotherapy termination and consolidation therapy initiation was 40.5 days (range: 2916–2923 © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
1–85 days). A total of 10 patients (50.0%) were treated via PD-L1 monoclonal antibody therapy (durvalumab, 10 mg/kg biweekly), while 10 patients (52.4%) were treated via PD-1 monoclonal antibody therapy (terepril, \( n = 5 \), 240 mg triweekly; sintilizumab, \( n = 3 \), 200 mg triweekly; nivolumab, \( n = 1 \), 240 mg biweekly; pembrolizumab, \( n = 1 \), 200 mg triweekly).

**Safety**

All adverse events in these patients are reported in Table 2. Adverse events of grade 3 or higher were rare during CRT, with only six patients (30.0%) experiencing grade 3 leukopenia, and with no other reports of radiation-associated grade 3 adverse events. The adverse events of patients are shown in Table 2.

During ICI consolidation therapy, 80.0% (\( n = 16 \)) of patients had pneumonitis of grade 1 or higher, of whom seven (35.0%) had grade 1 pneumonitis and nine (45.0%) had grade 2 pneumonitis. The median time to pneumonitis onset following ICI initiation was 72 (range: 23–120) days. Lung V20 \( \geq 20\% \) was associated with higher grade 2 pneumonitis (77.8% [in \( \geq 20\% \) group] vs. 18.2% [in <20% group], \( P = 0.027 \), Fig 1). All patients who experienced grade 2 pneumonitis were treated with prednisone (1 mg/kg) for >1 month.

Seven patients experienced additional immune-related toxicities, including six grade 1 toxicities and one grade 2 toxicity (chest pain). No grade 3 or higher immune-related adverse events occurred in this study.

**Response and survival**

The median follow-up period in this study was 11.3 (range: 6.2–21.8) months. A partial response (PR) was achieved in 14 (66.7%) patients, while complete response (CR) was achieved in five (25.0%) patients for an ORR (CR + PR) of 95.0% (Fig 2, two cases with CR are shown in Figs S1 and S2). Three patients ultimately developed metastatic disease within the study period, exhibiting metastases in the lung and bone and one patient died. The 12-month PFS of these patients was 89.5% (95% CI: 76.7%–100%), and 12-month OS was 100%.

**Discussion**

Immunotherapy has revolutionized cancer treatment, with ICIs including monoclonal anti-PD-1, anti-PD-L1, and anti-CTLA-4 having significantly improved survival outcomes in lung cancer and melanoma patients.16–18 In patients with advanced forms of lung cancer patients, combination ICIs and chemotherapy can significantly improve therapeutic efficacy and patient survival. Keynote-189 and Keynote-407 have revealed that the combination of pembrolizumab with chemotherapy significantly improved advanced NSCLC patient survival.18, 19 The combination of ICIs with concurrent or sequential CRT has been definitively established as an optimal treatment strategy for patients with locally advanced NSCLC, and this approach is generally well tolerated. Herein, we found that 12-month PFS in patients undergoing ICI consolidation therapy following CRT was 89.5%, which was promising given that the 12-month PFS observed in the PACIFIC study was 55.7%.10

The PACIFIC trial was a randomized, placebo-controlled, double-blinded, multicenter analysis of 713 locally advanced NSCLC patients which found that durvalumab

---

**Table 2** All-cause adverse events in study patients

| Grade of adverse event, No. (%) | All | Grades | Grades | Grades |
|--------------------------------|-----|--------|--------|--------|
| Phase of chemoradiation        |     |        |        |        |
| Esophagitis                    | 13  | 9 (45.0) | 4 (20.0) | 0 |
| Anemia                         | 7   | 4 (20.0) | 3 (15.0) | 0 |
| Thrombocytopenia               | 6   | 7 (35.0) | 2 (10.0) | 0 |
| Leukopenia                     | 17  | 3 (15.0) | 7 (35.0) | 6 (30.0) |
| Radiation dermatitis           | 6   | 5 (25.0) | 1 (5.0) | 0 |
| Phase of consolidation ICI     |     |        |        |        |
| Pneumonitis                    | 16  | 7 (35.0) | 9 (45.0) | 0 |
| Fatigue                        | 2   | 2 (10.0) | 0 | 0 |
| Cough                          | 2   | 2 (10.0) | 0 | 0 |
| Fever                          | 2   | 2 (10.0) | 0 | 0 |
| Thyroid dysfunction            | 1   | 1 (5.0) | 0 | 0 |
| Chest pain                     | 1   | 1 (5.0) | 0 | 0 |
consolidation significantly enhanced PFS following CRT regardless of PD-L1 expression status (median PFS: 16.8 months vs. 5.6 months; hazard ratio [HR] = 0.52, 95% CI: 0.42–0.65, \(P < 0.001\)). The LUN 14-179 study was a phase II single-arm prospective study evaluating pembrolizumab consolidation therapy safety and efficacy in stage III unresectable NSCLC patients not exhibiting disease progression after cCRT within a 12-month period. At a median follow-up of 18.6 months, median PFS was 17.0 months (95% CI: 11.9–NX), with 12–18- and 24-month PFS rates of 60.2%, 49.9%, and 44.6%, respectively. At the time of this analysis, median OS had not yet been reached, and 12–18- and 24-month OS rates were 81.0%, 68.0%, and 61.9%, respectively. At the time of the analysis, median OS had not yet been reached, and 12–18- and 24-month OS rates were 81.0%, 68.0%, and 61.9%, respectively.20 These two trials confirmed that ICIs including both anti-PD-1 and anti-PD-L1 could be used as consolidation therapy to prolong OS and PFS of patients with locally advanced NSCLC. In this study, we included patients treated with both anti-PD-1 and anti-PD-L1. A prior meta-analysis of 112 trials and 19 217 patients observed comparable fatality rates for both of these antibodies at 0.36% (anti-PD-1) and 0.38% (anti-PD-L1).21 We found similar rates of grade 2 pneumonitis in patients treated with anti-PD-1 and anti-PD-L1 (40.0% vs. 50.0%, \(P = 1.000\)). We observed a 95.2% ORR (CR + PR) in this study. In prior studies including some phase III trials, traditional CRT was associated with ORRs ranging from 35% to 70%, and CR rates were generally <10% (Table 3). Consolidation ICI therapy is thus a promising therapeutic approach in Chinese NSCLC patients.

Limited data is available regarding immunotherapy toxicity following radical CRT treatment in stage III NSCLC patients. In the LUN 14-179 phase II trial, 17.2% of patients experienced pneumonitis of grade \(\geq 2\), with 10.8%, 4.3%, and 1.1% of patients suffering from grade 2, 3, and 4 pneumonitis, respectively.12 In the PACIFIC study, 33.9% and 24.8% of patients experienced any form of pneumonitis and RP, respectively, with 3.4% and 2.6% of patients experiencing grades 3 and 4 pneumonitis, respectively.10 While overall pneumonitis incidence in our study was markedly higher (73.3%), we found that only 53.3% of patients experienced symptomatic pneumonitis (grade > 2), and no patients experienced severe pneumonitis (grade > 3). This is in line with the results of the post-hoc analyses of the Japanese subgroup in the PACIFIC trial, in which 47.9% of patients experienced pneumonitis.22 These results thus suggest that ICI consolidation therapy is safe and feasible in Chinese patients. A Japanese retrospective analysis of 108 patients found that rates of grade 1, 2, and

---

**Table 3** Studies of chemoradiotherapy for the treatment of stage III NSCLC

| Study        | Population | Radiation dose (Gy) | CR (%) | PR (%) | ORR (%) | Median PFS, (months) | Median OS, (months) |
|--------------|------------|---------------------|--------|--------|---------|----------------------|---------------------|
| RTOG 941028  | III NSCLC  | (n = 610)           | 63     | 42     | 28      | 70                   | NR                  | 17.0                |
| CALGB 398011 | III NSCLC  | (n = 182)           | 66     | 7      | 59      | 67                   | NR                  | 12.0                |
| LUN 01–2420  | III NSCLC  | (n = 74)            | 59.4   | NR     | NR      | NR                   | NR                  | 23.2                |
| PROCLAIM31   | IIIA/B NSCLC | (n = 598)       | 60–66  | 1.3    | 34.6    | 35.9                 | 11.4                | 26.8                |
| RTOG 061732  | IIIA/B NSCLC | (n = 228)       | 60     | NR     | NR      | NR                   | NR                  | 28.7                |
| KCSG-LU05-04 | IIIA/B NSCLC | (n = 437)       | 66     | 2.9    | 40.2    | 43.1                 | 9.1                 | 21.8                |

---

mo, months.
3 pneumonitis were 58%, 26%, and 1% with a V20 constraint of 35%. Another analysis of 31 patients found that pneumonitis occurred in 17.2% of all patients, and was of at least grade 3 in 6.9% of these patients. In Table 4 we have summarized the incidence of pneumonitis associated with ICI consolidation therapy in Asian patients in different studies. These analyses indicate that the pneumonitis rates range from 17.2% to 85% (pooled rate: 67.1%), with grade 3 or higher pneumonitis occurring in 0%–14.3% of patients (pooled rate: 4.4%, Table 4). The increase in pneumonitis rates in Asian populations relative to non-Asian populations may suggest that there are differences in the immune responses in these two groups. Finally, the PACIFIC study specified a lung V20 of ≤35% or a mean lung dose of ≤20 Gy. In the real-world of Korea study, researchers found that V20 ≥ 35% and MLD ≥ 20 Gy were associated with more grade 2 or higher-grade RP (61.9% vs. 15.0%; 70.6% vs. 15.9%). In our study, the higher V20 was associated with more grade 2 RP (V20 ≥ 20% vs. V20 < 20%; 77.8% vs. 18.2%, P = 0.027). We therefore propose that the total lung V20 to highest thresholds such as 28% or less is reasonable.

Further research regarding optimal ICI timing relative to radiotherapy administration is required. Updated OS data from the PACIFIC trial indicate that patients administered durvalumab ≤14 days following radiation survived for longer than patients treated within ≥14 days (HR 0.43, 95% CI: 0.26–0.66 vs. 0.79, 95% CI: 0.61–1.02). This suggests that earlier ICI administration is probably linked to maximal survival benefit. In a different phase I prospective multicenter nonrandomized controlled trial, pembrolizumab was combined with cCRT (weekly carboplatin and paclitaxel with standard radiotherapy). In this study, patients receiving at least one dose of pembrolizumab (n = 21) had a median PFS of 18.7 months (95% CI: 11.8–29.4), and the six- and 12-month PFS of this patient group was 81.0% (95% CI: 64.1%–97.7%) and 69.7% (95% CI: 49.3%–90.2%), respectively. The median PFS for patients receiving two or more doses of pembrolizumab (n = 19) was 21.0 (95% CI: 15.3–infinity) months. At present, the PACIFIC 2 trial (NCT03519971, phase III study) is being conducted in order to assess the efficacy and safety of durvalumab combined with concurrent platinum-based chemoradiation in patients with unresectable stage III NSCLC.

Herein, we explored the use of ICI consolidation therapy for the treatment of Chinese patients with inoperable stage III NSCLC. However, our sample size was limited, with just 20 patients having been included in this analysis. Of these patients, only 17 underwent PACIFIC model treatment, with the remaining three undergoing ICI consolidation following sequential chemoradiotherapy. Many patients in China with inoperable stage III NSCLC elect to undergo sequential radiotherapy and chemotherapy, while certain patients elect to undergo radiotherapy alone due to advanced age or poor overall health. Further research regarding ICI consolidation after sequential CRT or radiotherapy is still required. Furthermore, the majority of patients in the present study did not undergo analyses of intratumoral PD-L1 expression. Results from the PACIFIC study suggest that patients with >1% PD-L1 expression were more likely to benefit from immunotherapy. As such, PD-L1 expression in these patients should be evaluated further in subsequent studies.

In conclusion, ICI consolidation therapy is associated with favorable short-term efficacy, good safety, and acceptable toxicity profiles in Chinese patients with unresectable stage III NSCLC. While these patients experienced a higher incidence of pneumonitis than other previously reported populations, no severe pneumonitis was reported. Overall, our findings are consistent with prior studies of Asian populations and those of other ethnicities.

### Acknowledgments

This work was supported by CAMS Innovation Fund for Medical Sciences (2017-I2M-1-009) and Beijing Hope Run Special Fund of Cancer Foundation of China.

---

**Table 4** Pneumonitis in Asian stage III NSCLC following ICI consolidation therapy

| Study                  | Country (region) | Population | All pneumonitis (%) | G2 pneumonitis (%) | G3–5 pneumonitis (%) |
|------------------------|------------------|------------|---------------------|--------------------|----------------------|
| Fukui et al.           | Japan            | 108        | 85                  | 26.0               | 2.0                  |
| Chu et al.             | China (Taiwan)   | 31         | 17.2               | NR                 | 6.9                  |
| Jung et al.            | Korea            | 21         | 81                 | 42.9               | 14.3                 |
| Sakaguchi et al.       | Japan            | 73         | 73.9               | NR                 | 5.5                  |
| PACIFIC Japan cohort   | Japan            | 112        | 54.2               | NR                 | 5.6                  |
| Current study          | China            | 20         | 80.0               | 45.0               | 0                    |
| Pooled data            | Asian            | 365        | 67.1               | 31.2               | 4.4                  |
| PACIFIC                | Multicountry     | 476/709    | 33.9               | NR                 | 3.4                  |
| LUN14-179              | USA              | 92         | 10.8               | 6.5                |                      |

G2, grade 2; G3–5, grades 3–5; NR, not reported.
ICI consolidation after CRT in China

T. Zhang et al.

(LC2018A04), Sanming Project of Medicine in Shenzhen (No. SZSM201612063).

Disclosure

All authors have no conflict of interest to disclose.

References

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70 (1): 7–30.
2 Yang P, Allen MS, Aubry MC et al. Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128 (1): 452–62.
3 Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: The past, present, and future. J Thorac Oncol 2008; 3 (8): 917–28.
4 Yamamoto N, Nakagawa K, Nishimura Y et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan thoracic oncology group WJTOG0105. J Clin Oncol 2010; 28 (23): 3739–45.
5 Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17 (9): 2692–9.
6 Bradley JD, Hu C, Komaki RR et al. Long-term results of NRG oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without Cetuximab for Unresectable stage III non-small-cell lung cancer. J Clin Oncol 2020; 38 (7): 706–14.
7 Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol 2015; 25 (1): 11–7.
8 Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12 (12): 860–75.
9 Antonia SJ, Villegas A, Daniel D et al. Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379 (24): 2342–50.
10 Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377 (20): 1919–29.
11 Gray JE, Villegas A, Daniel D et al. Three-year overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol 2020; 15 (2): 288–93.
12 Durm GA, Althouse SK, Sadiq AA et al. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179. 2018;36(15):8500.
13 Lin S, Lin X, Clay D et al. OA01.06 DETERRED: Phase II trial combining Atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer. J Thorac Oncol 2018; 13 (10): S320–1.
14 Inoue H, Okamoto I. Immune checkpoint inhibitors for the treatment of unresectable stage III non-small cell lung cancer: Emerging mechanisms and perspectives. Lung Cancer 2019; 10: 161–70.
15 Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (2): 228–47.
16 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373 (1): 23–34.
17 Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: Optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017; 14 (8): 463–82.
18 Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378 (22): 2078–92.
19 Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379 (21): 2040–51.
20 Anouti B, Althouse S, Durm G, Hanna N. Prognostic variables associated with improved outcomes in patients with stage III NSCLC treated with chemoradiation followed by consolidation pembrolizumab: A subset analysis of a phase II study from the Hoosier cancer research network LUN 14-179. Clin Lung Cancer 2020; 21 (3): 288–93.
21 Wang DY, Salem J-E, Cohen JV et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol 2018; 4 (12): 1721–8.
22 Faehling M, Schulz C, Laack H et al. PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo after CRT. Pneumologie 2019; 73 (S01).
23 Fukui T, Hosotani S, Soda I et al. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab. Thorac Cancer 2020; 11 (4): 1005–14.
24 Chu C-H, Chiu T-H, Wang C-C et al. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer. Thorac Cancer 2020; 11 (6): 1541–9.
25 Jung HA, Noh J-M, Sun J-M et al. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. Lung Cancer 2020; 146: 23–9.
26 Jabbour SK, Berman AT, Decker RH et al. Phase 1 trial of Pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: A nonrandomized controlled trial. JAMA Oncol 2020; 6: 848.
27 Paz-Ares L, Spira A, Raben D et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 2020; 31 (6): 798–806.
28 Curran WJ, Paulus R, Langer CJ et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. *J Natl Cancer Inst* 2011; 103 (19): 1452–60.

29 Vokes EE, Herndon JE, Kelley MJ et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and leukemia group B. *J Clin Oncol* 2007; 25 (13): 1698–704.

30 Ahn JS, Ahn YC, Kim J-H et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent Chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. *J Clin Oncol* 2015; 33 (24): 2660–6.

31 Senan S, Brade A, Wang L-H et al. PROCLAIM: Randomized phase III trial of Pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. *J Clin Oncol* 2016; 34 (9): 953–62.

32 Bradley JD, Paulus R, Komaki R et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. *Lancet Oncol* 2015; 16 (2): 187–99.

33 Sakaguchi T, Ito K, Furuhashi K et al. Patients with unresectable stage III non-small-cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria. *Respir Investig* 2019; 57 (5): 466–71.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

**Supplementary Figure S1** This patient (Case 1) presented with T1cN3M0 adenocarcinoma and received Terepril consolidation after cCRT. This patient achieved complete response for both primary and lymph node target lesions.

**Supplementary Figure S2** This patient (Case 2) presented with T4N3M0 adenocarcinoma and received Durvalumab consolidation following concurrent chemoradiation and induction chemotherapy. This patient achieved complete response for both primary and lymph node target lesions.